British Columbia Cancer Agency Branch

Welichem Biotech Inc.

Signalchem Lifesciences Corporation

Paul Christopher McDonald

Shoukat Dedhar

Claudiu Supuran

Fabrizio Carta

Yuanmei Lou

Frances E Lock

Arusha Oloumi

The present disclosure provides methods for detecting the presence of a cancer stem cell and their use in cancer prognosis, evaluating risk of cancer metastasis, identifying or validating drug candidates, and determining treatment efficacy. It also provides kits useful for detecting the presence of cancer stem cells as well as methods of treating cancer using CAIX inhibitors.

Carbonic anhydrase IX-related markers and use thereof

Therapeutic ureido-sulfonamide compositions having compounds with the formulaR-Q-Ar&#x2014;SONHare disclosed, which compounds selectively inhibit CAIX and CAXII, and which are effective to inhibit hypoxic tumor growth, suppress metastases, and impair and deplete cancer stem cells in mammals.

Sulfonamide compounds for inhibition of metastatic tumor growth

There is provided a method for determining tumour metastatic potential using biomarkers of tumour metastasis comprising any two of carbonic anhydrase-9 (CAIX), vascular endothelial growth factor C (VEGF-C), ephrin A5 (EFNA5), eph receptor B2 (EPHB2), transforming growth factor beta 3 (TGF-&#x3b2;3), pyruvate dehydrogenase kinase isoenzyme-3 (PDK3), carbonic anhydrase-12 (CAXII), keratin 14 (KRT14), hypoxia inducible factor 1 alpha subunit (HIF-1&#x3b1;), and tenascin C (TNC). CAIX, VEGF-C, EFNA5, EPHB2, TGF-&#x3b2;3 or PDK3 may be indicators of moderate metastatic potential, while CAXII, KRT14, HIF-1&#x3b1;, or TNC may be indicators of high metastatic potential. The biomarkers may be used to assess malignancies or cancers having hypoxic regions, such as breast cancer.

Biomarkers of cancer metastasis

Growing community of inventors

Coquitlam, Canada

Paul Christopher McDonald